EUVIMEDEUVIMED entdecken
Open Access

Gemcitabine resistance in non‐small cell lung cancer is mediated through activation of the PI3K/AKT/NF‐κB pathway and suppression of ERK signaling by reactive oxygen species

Chih-Hao Chiu, Yu-Jung Lin, Samiraj Ramesh, Wei-Wen Kuo, Ming-Cheng Chen, Chia-Hua Kuo, Chi-Cheng Li, Tso-Fu Wang, Yueh-Min Lin, Po-Hsiang Liao, Chih-Yang Huang

Journal of Biochemical and Molecular Toxicology · 2023

DOI: 10.1002/jbt.23497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2023. Verfasst von Chih-Hao Chiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is one of the most common cancers in the world. Chemotherapy is a standard clinical treatment. However, tumor cells often develop multidrug resistance after chemotherapy, an inevitable bottleneck in cancer treatment. Therefore, this study used gemcitabine‐resistant (GEM‐R) CL1‐0 lung cancer cells. First, we used flow cytometry and western blot analysis to examine differences in performance between resistant and parental cells. The results showed that compared with parental cells, GEM‐R CL1‐0 cells significantly enhanced the activation of the AKT pathway, which promoted survival and growth, and decreased the activation of the reactive oxygen species‐extracellular signal‐regulated kinase (ROS)‐ERK pathway. Next, the AKT and ERK pathways' role in tumor growth was further explored in vivo using a xenograft model. The results showed that enhancing AKT and inhibiting ERK activation reduced GEM‐induced inhibition of tumor growth. Finally, combining the above results, we found that GEM‐R CL1‐0 cells showed reduced sensitivity to GEM by activating the phosphatidylinositol 3‐kinase/AKT/NF‐kB pathway and inhibiting the ROS‐ERK pathway leading to resistance against GEM. Therefore, the AKT and ERK pathways are potential targets for improving the sensitivity of cancer cells to anticancer drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansGemcitabineNF-kappa BReactive Oxygen SpeciesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesCell Line, TumorApoptosis

Stichwörter der Autor:innen

AKTCL1-0 lung cancer cellsERKgemcitabine-resistancereactive oxygen species

Substanzen

GemcitabineNF-kappa BReactive Oxygen SpeciesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
  • Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • School of Post-Baccalaureate Chinese Medicine, College of Medicine, Tzu Chi University, Hualien, Taiwan.
  • Department of Research and Innovation, Institute of Biotechnology, Saveetha School of Engineering (SSE), Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India.
  • Department of Biological Science and Technology, College of Biopharmaceutical and Food Sciences, China Medical University, Taichung, Taiwan.
  • Division of Colorectal Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.

Zitieren

APA

Chiu, C. H., Lin, Y. J., Ramesh, S., Kuo, W. W., Chen, M. C., Kuo, C. H., Li, C. C., Wang, T. F., Lin, Y. M., Liao, P. H., & Huang, C. Y. (2023). Gemcitabine resistance in non‐small cell lung cancer is mediated through activation of the PI3K/AKT/NF‐κB pathway and suppression of ERK signaling by reactive oxygen species. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23497

Vancouver

Chiu CH, Lin YJ, Ramesh S, Kuo WW, Chen MC, Kuo CH, et al. Gemcitabine resistance in non‐small cell lung cancer is mediated through activation of the PI3K/AKT/NF‐κB pathway and suppression of ERK signaling by reactive oxygen species. Journal of Biochemical and Molecular Toxicology. 2023. doi:10.1002/jbt.23497

BibTeX
@article{Chiu2023,
  author = {Chiu, Chih-Hao and Lin, Yu-Jung and Ramesh, Samiraj and Kuo, Wei-Wen and Chen, Ming-Cheng and Kuo, Chia-Hua and Li, Chi-Cheng and Wang, Tso-Fu and Lin, Yueh-Min and Liao, Po-Hsiang and Huang, Chih-Yang},
  title = {Gemcitabine resistance in non‐small cell lung cancer is mediated through activation of the PI3K/AKT/NF‐κB pathway and suppression of ERK signaling by reactive oxygen species},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2023},
  doi = {10.1002/jbt.23497}
}
Kostenlos starten →